KDM2B and mantle cell lymphoma: As shown in Fig. 6A, MYC introduction in erdafitinib-treated MCL cells causes higher levels of expression of KDM2B and EZH2 and subsequent loss of CDKN1C along with reactivation of CDK1 (RB/E2F1 target), suggesting that FGFR1 mediated regulation of KDM2B/EZH2/CDKN1C is MYC dependent.